Study the Pharmacokinetic Effect of Tangcao Tablet on Lopinavir in HIV-infected Patients

OBJECTIVE To investigate the pharmacokinetic effect of Tangcao tablet on lopinavir in HIV-infected patients. METHODS Enrolling HIV-infected patients with highly active antiretroviral therapy(HAART) including lopinavir up to steady state. Blood samples were obtained at 0, 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0 and 12.0 h, respectively after treating with lopinavir. The patients were given Tangcao tablet together with HAART thereafter for 2 weeks. Blood samples were obtained again and analyzed. The drug concentration was detected by liquid chromatography tandem mass spectrometry (LC-MS). The statistic analysis was performed by DAS2.1.1 software. RESULTS Sixteen eligible HIV-infected patients were enrolled. The AUC, C_max, T_max and T_1/2 of lopinavir were (100.12±57.72)mg·L^-1·h^-1, (13.24±8.35)mg·L^-1, (4.16±2.39)h, (9.62±7.57)h before taking Tangcao tablet and were (95.55±58.50)mg·L^-1·h^-1, (12.36±7.26)mg·L^-1, (4.06±3.06)h, (9.20±7.18)h after combination with Tangcao tablet, respectively. No significant difference was found between the two groups. CONCLUSION Tangcao tablet has no impact on the pharmacokinetics parameters of lopinavir in HIV-infected patients.